Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.47 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15451428 | 0.96 | NOD1 (0.57) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL16704748 | 0.96 | NOD1 (0.57) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL3287759 | 0.86 | FOLH1 (0.64) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL20539219 | 0.86 | FOLH1 (0.64) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL3287762 | 0.86 | FOLH1 (0.64) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL24235732 | 0.86 | CYP2C9 (0.41) | NOD1FOLH1NAALAD2RIMKLACYP2C9 | |
| SCHEMBL15451426 | 0.85 | NOD1 (0.61) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL32685330 | 0.85 | NOD1 (0.38) | NOD1FOLH1NAALAD2RIMKLAPIN1 | |
| SCHEMBL14683450 | 0.85 | NOD1 (0.47) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL17776319 | 0.85 | NOD1 (0.65) | NOD1FOLH1NAALAD2RIMKLAGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486505-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-9029325-B2 | Amylin analogues and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2015-05-12 | — | — | US | disclosed |
| US-9029325-B2 | Amylin analogues and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2015-05-12 | — | — | US | disclosed |
| US-9023789-B2 | Amylin analogs and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2015-05-05 | — | — | US | disclosed |
| US-9023789-B2 | Amylin analogs and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2015-05-05 | — | — | US | disclosed |
| US-20140087995-A1 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-03-27 | — | — | US | disclosed |
| US-20140087995-A1 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-03-27 | — | — | US | disclosed |
| US-20130281363-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281363-A1 | POLYPEPTIDES | IAPP, GLP1R, AMY2A | NOD1 2327/4885FOLH1 461/4885NAALAD2 469/4885 |
| US-20140087995-A1 | Polypeptides | IAPP, GLP1R, AMY2A | NOD1 2327/4885FOLH1 461/4885NAALAD2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.